visfatin蛋白質的過度表現是上泌尿道上皮癌預後不佳的因子
柯宏龍1,2,5、林慧惠2,5、李威明1,2,5,8、李經家1,2,5,6、張玲麗1,4、李怡琛3、黃俊農1,2,5、吳文正1,2,5,7
高雄醫學大學 醫學研究所1 泌尿學科2 解剖學科3 微生物學科4
高雄醫學大學附設醫院泌尿科5、大同醫院泌尿科6、小港醫院泌尿科7、署立屏東醫院泌尿科8
Prognostic value of visfatin protein overexpression in upper tract urothelial carcinomas in Taiwan
Hung-Lung Kea,c,e , Hui-Hui Linc,e , Wei-Ming Lia,c,e,h ,Ching-Chia Li a,c,e,g, Lin-Li Changa,d , Yi-Chen Leea,b, Chun-Nung Huang a,c,e, Wen-Jeng Wua,c,e,f
aGraduate Institute of Medicine, bDepartment of Anatomy , cDepartment of Urology , dDepartment of Microbiology , College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan eDepartment of Urology, Kaohsiung Medical University Hospital, fDepartment of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, gDepartment of Urology, Kaohsiung Municipal Ta-Tung Hospital, , Kaohsiung Medical University, Kaohsiung, Taiwan hPingtung Hospital , Department of Health, Executive Yuan, Pingtung , Taiwan
Purpose:
Visfatin, a newly discovered adipocytokine, is a pro-inflammatory cytokine. This study aimed to evaluate the predictive value of visfatin on prognosis of patients with upper tract urothelial carcinoma.
Materials and Methods:
One-hundred and five patients (median age=64, range=24-84 years) were included in this study. Visfatin expression in upper tract urothelial carcinoma tissues was analyzed by immunohistochemistry. Visfatin expression was correlated with clinicopathologic variables using the χ2 test. The prognostic value of visfatin for recurrence-free and cance-specific survival was evaluated by Kaplan-Meier estimates, and the significance of differences between curves was evaluated by the log-rank test. Cox regression model was also used to evaluate the hazard ratios of visfatin on survival.
Results:
High visfatin expression in upper tract urothelial carcinoma tissues was significantly correlated with tumor stage (p=0.001), grade (p=0.007) and p53 expression (p=0.07). High visfatin expression was associated with poor recurrence-free and cancer-specific survival. Cox regression analysis also revealed that visfatin is an independent predictor of recurrence-free (HR=3.22, p=0.009) and cancer-specific survival (HR=5.74, p=0.023).
Conclusion:
Our findings indicated that higher visfatin expression is a potential biomarker to predict patient survival. Further study is necessary to investigate the molecular mechanisms of visfatin involved in the cancerous processes of upper tract urothelial carcinoma.